| BID | 4.47 | ASK | 4.57 | ||
| Open | 4.59 | Previous Close | 4.52 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 14.00 | Analyst Rating | Strong Buy 1.40 | |
| Potential % | 207.02 | Finscreener Ranking | ★★+ 48.21 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 43.89 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 36.84 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 28.34M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 7.78 | Earnings Date | 12th May 2021 |
Today's Price Range 4.404.60 | 52W Range 3.7813.80 | 5 Year PE Ratio Range -1.10-1.30 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.87% | ||
| 1 Month | -25.41% | ||
| 3 Months | -29.38% | ||
| 6 Months | -7.57% | ||
| 1 Year | -8.51% | ||
| 3 Years | -90.81% | ||
| 5 Years | -89.20% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -195.64 | |||
ROE last 12 Months | -102.86 | |||
ROA (5Y Avg) | -51.66 | |||
ROA last 12 Months | -49.50 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -60.18 | |||
Return on invested Capital Q | -14.66 | |||
Return on invested Capital Y | -65.14 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.20 | ||||
| 2.18 | ||||
| 4.85 | ||||
| - | ||||
| -2.50 | ||||
| -3.52 | ||||
| 2.18 | ||||
| 2.33 | ||||
| 15.58M | ||||
| Forward PE | -1.27 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.20 | ||||
| 4.50 | ||||
| 0.38 | ||||
| 0.87 | ||||
| -19.40 | ||||
| Leverage Ratio | 2.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 53.30 | ||||
| -185.40 | ||||
| -168.20 | ||||
| -211.30 | ||||
| -87.04 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.32M | ||||
| 1.02 | ||||
| -20.31 | ||||
| 26.69 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | -1.05 | -1.05 | 0.00 |
| Q02 2020 | -1.20 | -1.20 | 0.00 |
| Q01 2020 | -1.20 | -1.20 | 0.00 |
| Q04 2019 | -1.20 | -0.15 | 87.50 |
| Q03 2019 | -2.10 | -2.25 | -7.14 |
| Q02 2019 | -0.15 | -0.17 | -13.33 |
| Q01 2019 | -0.17 | -0.19 | -11.76 |
| Q04 2018 | -0.20 | -0.07 | 65.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.95 | 0.00 | - |
| 6/2021 QR | -0.87 | -2.35 | Negative |
| 12/2021 FY | -3.15 | -10.53 | Negative |
| 12/2022 FY | -3.89 | - | - |
| Next Report Date | 12th May 2021 |
| Estimated EPS Next Report | -0.95 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 6.01K |
| Shares Outstanding | 6.21M |
| Trades Count | 62 |
| Dollar Volume | 870.75K |
| Avg. Volume | 159.87K |
| Avg. Weekly Volume | 47.73K |
| Avg. Monthly Volume | 139.37K |
| Avg. Quarterly Volume | 138.54K |
HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) stock closed at 4.52 per share at the end of the most recent trading day (a -6.03% change compared to the prior day closing price) with a volume of 65.42K shares and market capitalization of 28.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 108 people. HTG Molecular Diagnostics Inc. CEO is John L. Lubniewski.
The one-year performance of HTG Molecular Diagnostics Inc. stock is -8.51%, while year-to-date (YTD) performance is -5.64%. HTGM stock has a five-year performance of -89.2%. Its 52-week range is between 3.78 and 13.8, which gives HTGM stock a 52-week price range ratio of 7.78%
HTG Molecular Diagnostics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 2.18, a price-to-sale (PS) ratio of 4.85, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -49.50%, a ROC of -60.18% and a ROE of -102.86%. The company’s profit margin is -87.04%, its EBITDA margin is -168.20%, and its revenue ttm is $6.32 Million , which makes it $1.02 revenue per share.
Of the last four earnings reports from HTG Molecular Diagnostics Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.95 for the next earnings report. HTG Molecular Diagnostics Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for HTG Molecular Diagnostics Inc. is Strong Buy (1.4), with a target price of $14, which is +207.02% compared to the current price. The earnings rating for HTG Molecular Diagnostics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
HTG Molecular Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
HTG Molecular Diagnostics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.14, ATR14 : 0.54, CCI20 : -150.63, Chaikin Money Flow : -0.27, MACD : -0.45, Money Flow Index : 69.05, ROC : -14.56, RSI : 38.47, STOCH (14,3) : 4.15, STOCH RSI : 0.00, UO : 50.48, Williams %R : -95.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of HTG Molecular Diagnostics Inc. in the last 12-months were:
HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics Inc is a commercial-stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. The company derives revenue from services provided by its VERI/O laboratory and sales of the company's automation systems and integrated next-generation sequencing-based HTG EdgeSeq assays. It operates in one segment and its customers are primarily located in the United States and Europe.
CEO: John L. Lubniewski
Telephone: +1 877 289-2615
Address: 3430 E. Global Loop, Tucson 85706, AZ, US
Number of employees: 108
